Sangamo Therapeutics (SGMO) EBIAT (2016 - 2025)
Historic EBIAT for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.
- Sangamo Therapeutics' EBIAT fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
- Per Sangamo Therapeutics' latest filing, its EBIAT stood at -$34.9 million for Q3 2025, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
- Sangamo Therapeutics' 5-year EBIAT high stood at $21.1 million for Q1 2023, and its period low was -$114.5 million during Q2 2023.
- Over the past 5 years, Sangamo Therapeutics' median EBIAT value was -$44.0 million (recorded in 2022), while the average stood at -$42.7 million.
- Per our database at Business Quant, Sangamo Therapeutics' EBIAT plummeted by 297664.52% in 2021 and then skyrocketed by 14805.47% in 2023.
- Quarter analysis of 5 years shows Sangamo Therapeutics' EBIAT stood at -$37.5 million in 2021, then tumbled by 38.61% to -$52.0 million in 2022, then dropped by 16.01% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
- Its last three reported values are -$34.9 million in Q3 2025, -$20.0 million for Q2 2025, and -$30.6 million during Q1 2025.